Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial)
European Urology Focus · 2026
DOI: 10.1016/j.euf.2025.08.009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Urology Focus, 2026. Verfasst von Kathrin Bausch und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: kathrin.bausch@usb…. Hauptthemen laut MEDLINE: Transurethral Resection of Prostate, Urinary Tract Infections, Antibiotic Prophylaxis, Laser Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Guidelines recommend single-dose antimicrobial prophylaxis (AMP) for transurethral resection (TURP) and photoselective vaporization (PVP) of the prostate. As guideline adherence is low and 3-d AMP is given frequently, we aimed to assess the noninferiority of a single dose compared with 3-d AMP by comparing the incidence of urinary tract infections (UTIs) within 30 d. METHODS: A double-blind, multicenter, randomized, noninferiority trial was conducted comparing single-dose with 3-d AMP in patients assigned to TURP and PVP, assuming a 9% event rate for a clinical diagnosis of a UTI with a 4.4% noninferiority margin. KEY FINDINGS AND LIMITATIONS: From anticipated 1574 patients, 728 were recruited and 621 randomized patients were analyzed fully. The study was preliminary stopped due to delayed recruitment and was analyzed exploratively. Following single-dose AMP, 11.0% of patients (95% confidence interval [CI] 7.9%, 15.0%; 33/300) had a clinical diagnosis of UTIs, compared with 8.5% (95% CI 5.8%, 12.1%; 26/307) receiving 3-d AMP (between-group difference 2.5% [95% CI -2.2%, 7.5%]). The rates of UTIs supported by bacteriuria were lower without any difference between groups (single-dose AMP: 3.3% [95% CI 1.8%, 6.0%]; 3-d AMP: 3.3% [95% CI 1.8%, 5.9%]; between-group difference 0.08% [95% CI -2.97%, 3.16%]). Adverse events were rare. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this randomized trial of transurethral prostate surgery patients, 11.0% of those on single-dose AMP and 8.5% on 3-d AMP were diagnosed with UTIs. The smaller than planned sample size precludes a definite interpretation favoring either group. Diagnoses of UTIs based on symptoms and bacteriuria reduced the overall rates and group differences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland. Electronic address: kathrin.bausch@usb.ch.
- University of Basel, Basel, Switzerland; CLEAR Methods Center and Surgical Outcome Research Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Bas…
- Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
- University of Basel, Basel, Switzerland; Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Urology, University Hospital Basel, Basel, Switzerland.
- University of Basel, Basel, Switzerland; Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland; Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany.
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Bausch, K., Speich, B., Vogt, D. R., Hemkens, L. G., Dreher, M., Kwiatkowski, M., Subotic, S., Ardelt, P., Bossard, P., Hermanns, T., Bruni, N., Wyler, S., Prause, L., Merz, S. C., Engesser, C., Roth, J., Widmer, A. F., & Seifert, H. H. (2026). Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial). European Urology Focus. https://doi.org/10.1016/j.euf.2025.08.009
Vancouver
Bausch K, Speich B, Vogt DR, Hemkens LG, Dreher M, Kwiatkowski M, et al. Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial). European Urology Focus. 2026. doi:10.1016/j.euf.2025.08.009
BibTeX
@article{Bausch2026,
author = {Bausch, Kathrin and Speich, Benjamin and Vogt, Deborah R and Hemkens, Lars G and Dreher, Maeve and Kwiatkowski, Maciej and Subotic, Svetozar and Ardelt, Peter and Bossard, Piet and Hermanns, Thomas and Bruni, Nicole and Wyler, Stephen and Prause, Lukas and Merz, Sarah-Charlotte and Engesser, Christian and Roth, Jan and Widmer, Andreas F and Seifert, Hans-Helge},
title = {Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial)},
journal = {European Urology Focus},
year = {2026},
doi = {10.1016/j.euf.2025.08.009}
}
EUVIMED